| アブストラクト | The study objective was to compare the long-term incidence and risk of mortality and cardiovascular outcomes in patients with hypertension initiating bisoprolol, other beta-blockers or other antihypertensive therapies. Cohort analysis using UK Clinical Practice Research Datalink (CPRD). Adult patients with first diagnosis of hypertension recorded between 2000 and 2014, with >/=365days of registration to first event and initiating monotherapies of bisoprolol, other beta-blockers or drugs other than beta-blockers within 6 months of diagnosis were included. Incidence rates (IR) for each treatment cohort were compared using adjusted hazard ratio (HR) and 95% confidence intervals (CI) obtained from Cox regression analyses. Of 100,066 patients included, 539 were prescribed bisoprolol, 3701 other beta-blockers, and 95,826 drugs other than beta-blockers. Patients receiving bisoprolol had significantly increased survival from 2 up to <15 years (HR for <15 years 0.34; 95% CI 0.18-0.67) versus other beta-blockers, and from 5 to <15 years (HR for <15 years 0.52; 95% CI 0.27-1.00) versus drugs other than beta-blockers. Over time, the risk of arrhythmia was higher in the bisoprolol cohort versus other beta-blockers, and risks of arrhythmia and angina were higher versus drugs other than beta-blockers. No differences in the risk of embolism, stroke, and myocardial infarction (MI) were found between cohorts. Over time, mortality and cardiovascular outcome IRs decreased in each cohort. In conclusion, bisoprolol showed sustained benefit on survival, evident from 2 years after treatment initiation versus other beta-blockers, and from 5 years versus drugs other than beta-blockers, providing long-term evidence supporting the use of bisoprolol in patients with hypertension in primary care. |
|---|
| 組織名 | Merck KGaA, Darmstadt, Germany. Electronic address:;meritxell.sabido-espin@merckgroup.com.;Merck KGaA, Darmstadt, Germany.;Clinica Medica, University of Milano-Bicocca, Milan, Italy; IRCCS Multimedica,;Sesto San Giovanni, Milan, Italy. |
|---|
